Cytogenetic abnormalities correlate with clinico-biological characteristics in 30 Moroccan multiple myeloma patients.
Chromosomal abnormalities
Clinic-biological characteristics
Fluorescence in situ hybridization (FISH)
Multiple myeloma
Journal
Leukemia research reports
ISSN: 2213-0489
Titre abrégé: Leuk Res Rep
Pays: England
ID NLM: 101608906
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
08
2023
accepted:
20
10
2023
medline:
30
11
2023
pubmed:
30
11
2023
entrez:
30
11
2023
Statut:
epublish
Résumé
The nonrandom recurrence of chromosomal abnormalities in multiple myeloma (MM) raises the possibility that they play a role in the pathophysiology and development of the disease. Fluorescence in situ hybridization (FISH) can identify a high frequency of certain abnormalities without the need for the proliferative and infiltrative index of malignant plasma cells required for conventional cytogenetic analysis. In this study, we describe the association between clinico-biological characteristics and chromosomal abnormalities in 30 Moroccan patients. The analysis of cytogenetic data, conventional and molecular, of 30 cases of MM, obtained from our previously cytogenetic study, and correlation of the results with the clinico-biological data of these patients. The bone marrow of 5 of 21 patients (23 %) contained a chromosomally abnormal clone, and all karyotypes were complicated (>3 abnormalities). Interphase FISH (iFISH) has detected aberrations in 14 out of 30 (46 %) of the total cases. The proportion of plasma cells in the bone marrow was higher in patients with chromosomal abnormalities (median 29 %) ( Our research has shown that different subgroups of patients with MM can be classified based on the underlying genetic abnormalities. Chromosomal abnormalities (CA) may give the plasma cell a proliferative advantage, increasing the virulence of the disease and affecting overall survival.
Sections du résumé
Background
UNASSIGNED
The nonrandom recurrence of chromosomal abnormalities in multiple myeloma (MM) raises the possibility that they play a role in the pathophysiology and development of the disease. Fluorescence in situ hybridization (FISH) can identify a high frequency of certain abnormalities without the need for the proliferative and infiltrative index of malignant plasma cells required for conventional cytogenetic analysis. In this study, we describe the association between clinico-biological characteristics and chromosomal abnormalities in 30 Moroccan patients.
Methods
UNASSIGNED
The analysis of cytogenetic data, conventional and molecular, of 30 cases of MM, obtained from our previously cytogenetic study, and correlation of the results with the clinico-biological data of these patients.
Results
UNASSIGNED
The bone marrow of 5 of 21 patients (23 %) contained a chromosomally abnormal clone, and all karyotypes were complicated (>3 abnormalities). Interphase FISH (iFISH) has detected aberrations in 14 out of 30 (46 %) of the total cases. The proportion of plasma cells in the bone marrow was higher in patients with chromosomal abnormalities (median 29 %) (
Conclusion
UNASSIGNED
Our research has shown that different subgroups of patients with MM can be classified based on the underlying genetic abnormalities. Chromosomal abnormalities (CA) may give the plasma cell a proliferative advantage, increasing the virulence of the disease and affecting overall survival.
Identifiants
pubmed: 38035181
doi: 10.1016/j.lrr.2023.100392
pii: S2213-0489(23)00032-8
pmc: PMC10685041
doi:
Types de publication
Case Reports
Langues
eng
Pagination
100392Informations de copyright
© 2023 Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Leukemia. 2014 May;28(5):981-92
pubmed: 24177258
Oncotarget. 2015 Oct 27;6(33):34276-87
pubmed: 26416457
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Blood. 2007 Apr 15;109(8):3489-95
pubmed: 17209057
Nat Commun. 2015 Apr 23;6:6997
pubmed: 25904160
Leukemia. 2013 Mar;27(3):711-7
pubmed: 23032723
Int J Lab Hematol. 2019 Feb;41(1):5-14
pubmed: 29971938
Blood. 2003 Jun 1;101(11):4569-75
pubmed: 12576322
Cancer Genet. 2020 Apr;242:15-24
pubmed: 31980417
Nat Genet. 1997 Jul;16(3):260-4
pubmed: 9207791
Rev Bras Hematol Hemoter. 2016 Apr-Jun;38(2):113-20
pubmed: 27208569
Leukemia. 2003 Feb;17(2):427-36
pubmed: 12592343
Mol Genet Genomic Med. 2020 Sep;8(9):e1363
pubmed: 32573970
Blood. 2002 Sep 1;100(5):1579-83
pubmed: 12176874
J Clin Pathol. 2008 Jul;61(7):832-6
pubmed: 18077770
Cancer Genet Cytogenet. 1999 Aug;113(1):73-7
pubmed: 10459351
Blood. 2007 Mar 15;109(6):2276-84
pubmed: 17105813
Clin Cancer Res. 2011 Mar 15;17(6):1234-42
pubmed: 21411439
Blood. 2016 Jun 16;127(24):2955-62
pubmed: 27002115